Nigericin sodium salt is an antibiotic, an NLRP3 activator, and a cationic ion carrier. Nigericin sodium triggers the activation of the NALP3 inflammasome, which inhibits Golgi function and suppresses the growth of Gram-positive bacteria.

METHODS: Triple-negative breast cancer cells MDA-MB-231 and 4T1 were treated with Nigericin sodium (0.25-20 μg/mL) for 24 h. The cell viability of the cells was detected by the MTS.
RESULTS: Nigericin sodium dose-dependently inhibited the cell viability of MDA-MB-231 and 4T1 cells with IC50 of 2.881 μM and 2.505 μM, respectively. [1]
METHODS: Human lung cancer cells H460 were treated with Nigericin sodium (1 μM) for 24-48 h. Cell migration and invasion were detected by Transwell.
RESULTS: Nigericin sodium significantly inhibited the migration and invasion of H460 cells. [2]

METHODS: To detect anti-tumor activity in vivo, Nigericin sodium (2 mg/kg, subcutaneous injection every two days) and anti-PD-1 (250 μg/mouse, intraperitoneal injection once a week) were administered to BALB/c mice bearing triple-negative mammary adenocarcinoma tumor 4T1 for two weeks.
RESULTS: PD-1 antibody alone did not show significant antitumor effects, while Nigericin sodium showed moderate antitumor effects.The combination of Nigericin sodium and anti-PD-1 almost completely inhibited tumor growth. [1]
METHODS: To investigate the effects of aging on inflammatory vesicle function, Nigericin sodium (0.005 mg/g, 250 μL) was administered as a single intraperitoneal injection once daily for seven days to influenza virus-infected BALB/c mice.
RESULTS: Treatment with Nigericin sodium during influenza infection increased IL-1β production, increased capase-1 activity, and reduced morbidity and mortality in aged mice. During influenza virus infection, NLRP3 inflammatory vesicle activity is impaired in aged mice, and Nigericin sodium treatment rescues NLRP3 in aged hosts.[3]